The former R&D head of GSK’s vaccine unit is going toe-to-toe with his former employer, launching a rival vaccine-centered biotech that’s immediately challenging one of the U.K. pharma's late-stage programs.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,